FDAsafety guidance83% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Dizal Pharmaceuticals.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · B-cell Non-Hodgkin Lymphoma
- Sub-indication
- General
Related signal: Dizal Pharmaceuticals initiates trial for DZD8586 in relapsed B-cell Non-Hodgkin Lymphoma